Christine, go girl, that was a good report you sent....your friend, lillian
----------
> From: Christine White <christine.white@sympatico.ca>
> To: mol-cancer@lists.meds.com
> Subject: Re: [MOL] information - octreotide
> Date: Sunday, December 27, 1998 7:30 PM
>
> Here is an excerpt about some of the risks of octreotide. One of them
does
> have to do with the thyroid. Hope this is of some help.
>
> Christine
>
>
> Risks Associated with Octreotide: Octreotide may produce reactions at
the
> site of your shot, including pain, redness, and swelling. Diarrhea is a
> common side effect that often decreases over time, even when patients
> receive additional doses of octreotide. The diarrhea can usually be
managed
> with anti-diarrheal drugs. Other possible reactions to octreotide include
> nausea, vomiting, abdominal pain and bloating, decreased absorption of
fat,
> constipation, and increased gas.
>
> Patients taking octreotide are thought to be more likely to develop
> gallbladder problems, including gallstones and bile problems. It is
> estimated that 20-30% of patients taking octreotide may develop
gallstones.
> Additional patients (25-35%) may develop bile problems without
gallstones.
> Many patients taking octreotide have nausea, vomiting, abdominal
> discomfort, and gas (as noted in the previous paragraph), even without
> gallbladder problems. Symptoms of gallbladder disease include abdominal
> pain (often beginning within a few hours after meals), nausea, vomiting,
> fever, and yellowing of the skin. Bloating, belching, gas, and
intolerance
> for fatty foods may occur but are not specific for gallbladder problems.
> Gallbladder inflammation, gallbladder infection, inflammation of the
liver
> and/or pancreas may occur. Some patients may require hospitalization and
> possibly surgery to remove their gallbladder. A few patients taking
> octreotide have had life-threatening side effects. Rarely, death has
> occurred. Gallbladder and bile symptoms may develop after octreotide is
> discontinued. Patients who are known to have gallstones before taking
> octreotide can enter this study if they have never had symptoms. It is
not
> known whether these patients with gallstones at the start of the study
will
> be at more risk for developing symptoms from gallstones than patients who
> develop gallstones or bile problems after entering the study.
>
> Octreotide may cause low or high blood sugar in patients with diabetes as
> well as in non-diabetic patients, though the risk may be greater in
> diabetics. When compared with non-diabetic patients, diabetic patients,
> diabetic patients receiving insulin are at more risk for low blood sugar,
> which can be life-threatening. Your doctor may need to prescribe new
> medication(s), or change the dose of medication(s) you already take for
> diabetes. Octreotide may cause decreased thyroid function. Your doctor
may
> need to prescribe new medication(s), or change the dose of medication(s)
> you already take for thyroid problems. Changes in heart rhythm have been
> reported in patients with a specific hormone disorder (called acromegaly)
> who were being treated with octreotide. Changes in the dose of some blood
> pressure or heart medications may be necessary. In addition, decreased
> vitamin B12 levels, flushing, dizziness and lightheadedness, fatigue,
> headache, body aches, hair thinning/loss, allergic reactions, and
> occasional water retention can occur.
>
> It is not known whether octreotide will increase, decrease, or have no
> effect on the rate of uterine cancer in patients taking tamoxifen.
>
> >----------
> >> From: hardset <hardset@k0r3dump.org>
> >> To: mol-cancer@lists.meds.com
> >> Subject: [MOL] information
> >> Date: Wednesday, January 03, 1996 1:02 PM
> >>
> >> Hi,
> >>
> >> My mother is taking the octreotide injection for the clinicaltrial,
for a
> >> year and seven months. She has had radiation and is on tamoxen. Her
> >> breast cancer was hormone positive and in the last six months she has
> >been
> >> losing weigth and her thyroid is not functioning. I am worried and
would
> >> really appreciate any information on the octreotide injection and how
> >other
> >> patients are responding in the trial. The more education we can
receive
> >> the better.
> >>
> >> Thank you for your cooperation. Monique
> >> Alexander
> >> 337 read ave.
> >> Espanola, Ont.,
> >> P5E 1E2
> >>
> >>
------------------------------------------------------------------------
> >> This is an automatically-generated notice. If you'd like to be
removed
> >> from the mailing list, please visit the Medicine-On-Line Discussion
Forum
> >> at <http://www.meds.com/con_faq.html>, or send an email message to:
> >> majordomo@lists.meds.com
> >> with the subject line blank and the body of the message containing the
> >line:
> >> unsubscribe mol-cancer your-email-address
> >> where the phrase your-email-address is replaced with your actual email
> >> address.
> >>
------------------------------------------------------------------------
> >------------------------------------------------------------------------
> >This is an automatically-generated notice. If you'd like to be removed
> >from the mailing list, please visit the Medicine-On-Line Discussion
Forum
> >at <http://www.meds.com/con_faq.html>, or send an email message to:
> >majordomo@lists.meds.com
> >with the subject line blank and the body of the message containing the
line:
> >unsubscribe mol-cancer your-email-address
> >where the phrase your-email-address is replaced with your actual email
> >address.
> >------------------------------------------------------------------------
> >
>
> ------------------------------------------------------------------------
> This is an automatically-generated notice. If you'd like to be removed
> from the mailing list, please visit the Medicine-On-Line Discussion Forum
> at <http://www.meds.com/con_faq.html>, or send an email message to:
> majordomo@lists.meds.com
> with the subject line blank and the body of the message containing the
line:
> unsubscribe mol-cancer your-email-address
> where the phrase your-email-address is replaced with your actual email
> address.
> ------------------------------------------------------------------------
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
